Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
Sponsor: Centre Hospitalier Universitaire de Nice
Summary
his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp
Official title: Open, Prospective Study Evaluating the Efficacy and Safety of 0.05% Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-02-16
Completion Date
2027-12-16
Last Updated
2026-06-22
Healthy Volunteers
No
Conditions
Interventions
Tirbanibulin
Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
Locations (1)
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-maritimes, France